

**DCF Psychotropic Medication Advisory Committee
Monthly Meeting Notes**

May 6, 2011 1:30PM

Riverview Hospital for Children and Youth
Middletown, CT.

PRESENT: See enclosed attendance record.

1. Call to order: Dr. Siegel called the meeting to order at 1:14 pm.
2. Next Meeting: The next meeting will take place on June 3rd.
3. The minutes of the April 2011 PMAC meeting were reviewed and approved with corrections. Change cap letters to non-caps for generic drug names.
4. Announcements: Dr. Siegel met with Jillian Wood and Dr. Wolman about organizing a four part noon-time teleconference for pediatric practices on psychotropic medications, the fundamentals of DCF, the workings of the CMCU, and other relevant topics. She indicated that help from the PMAC will be needed. Jillian will be invited to the September 2011 meeting.

Lisa Honigfeld, Ph.D and Judith Meyers, Ph.D., of CHDI (the Child Health and Development Institute of Connecticut, a subsidiary of the Children's Fund of Connecticut) met with Dr. Wolman and Dr. Siegel regarding collaboration between DCF and CHDI. Dr. Honigfeld gave out a copy of her 2010 monograph titled "Integrating Behavioral Health and Primary Care: Making it Work in Four Practices in Connecticut"(available on their website). They requested the meeting to talk about future collaboration, as improving behavioral health care in primary care practices is a CHDI goal. They were very impressed by the guide on medications for parents this committee developed, and will begin distributing it (plus they put it on their website). Lisa and Judith will be invited to a future PMAC meeting – possibly October 2011.

5. DSS: New items Deferred. Some issues from the last meeting were discussed. Some pharmacoeconomic issues were also discussed.
6. Recommended Changes to the Approved Drug List:
 - Deletions.
 - Loxapine, Thiothixene, Chlordiazepoxide, Amantadine: Defer deleting any medications from the list until PMAC bylaws and drug list criteria have been reviewed.
 - Additions. Drug information monographs were distributed for each of the medications noted below.
 - Paliperidone (Invega): this medication has received FDA approval for use in children. Cost vs risperidone discussed. A vote was taken and this medication is **approved** for addition to the Approved Drug List.

- Venlafaxine: There was one study noted that compared venlafaxine to methylphenidate for treating ADHD. Efficacy was comparable and methylphenidate had a higher rate of side effects. Efficacy, discontinuation syndrome and other issues were discussed. Safety and efficacy in children and adolescents discussed in detail. Efficacy seen in some patients and community use is up. Paxil was briefly discussed and will not be added to the approved drug list. A vote was taken and venlafaxine in all dosage forms is **approved** for addition to the Approved Drug List.
- Asenapine: Monograph distributed and discussed in detail. No data available for use in children. This is not a unique or superior medication to those already on the Approved Drug List. Note this is a buccal or sublingual dosage form and has a very bad taste. Noted there is a very low bioavailability buccally and zero if ingested. Also the patient may not eat or drink immediately after a dose. Noted there is Zydys and M-Tabs on the approved drug list. A vote was taken and this medication will **not be added** to the Approved Drug List.
- Lurasidone : This medication has been on the market for less than 1 year. There is no data available regarding use in children and adolescents. Noted that this medication must be taken with at least a 300 calorie meal to get appropriate absorption. This medication may also increase prolactin levels. A vote was taken and this medication will **not be added** to the Approved Drug List.

7. Drug Status on the Approved Drug List: Proposed status categories: Defer

8. ADR Report: A cumulative report of ADR's reported in the 13-month period Oct 09 thru Oct 10 was distributed and discussed. A recommendation was made and accepted to combine this data with ADR data from Riverview Hospital for Children and Youth and CJTS. Amy Veivia will follow-up with Dr. Azeem and Hancock's Pharmacy regarding getting this additional ADR data.

9. Other:

- Bylaws: A recommendation was made and accepted to devote the entire June 2011 to a review of the PMAC Bylaws.
- Activity log: A recommendation was made and accepted to put together a log of the activities of the PMAC over the past several years. The purpose of this log is to evaluate the impact of PMAC activities on the care of DCF clients taking psychotropic medications.

10. Adjournment: The meeting was adjourned at 235pm.

Respectfully Submitted:

David S. Aresco